Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 43

Cited In for PubMed (Select 20862329)

1.

Genetic Variants and Related Biomarkers in Sporadic Alzheimer's Disease.

Guerreiro R, Bras J, Toombs J, Heslegrave A, Hardy J, Zetterberg H.

Curr Genet Med Rep. 2015;3:19-25. Review.

2.

Genome-wide association study of CSF levels of 59 alzheimer's disease candidate proteins: significant associations with proteins involved in amyloid processing and inflammation.

Kauwe JS, Bailey MH, Ridge PG, Perry R, Wadsworth ME, Hoyt KL, Staley LA, Karch CM, Harari O, Cruchaga C, Ainscough BJ, Bales K, Pickering EH, Bertelsen S; Alzheimer's Disease Neuroimaging Initiative, Fagan AM, Holtzman DM, Morris JC, Goate AM.

PLoS Genet. 2014 Oct 23;10(10):e1004758. doi: 10.1371/journal.pgen.1004758. eCollection 2014 Oct.

3.

Update on the core and developing cerebrospinal fluid biomarkers for Alzheimer disease.

Babić M, Svob Štrac D, Mück-Šeler D, Pivac N, Stanić G, Hof PR, Simić G.

Croat Med J. 2014 Aug 28;55(4):347-65. Review.

4.

Alzheimer's disease genetics: from the bench to the clinic.

Karch CM, Cruchaga C, Goate AM.

Neuron. 2014 Jul 2;83(1):11-26. doi: 10.1016/j.neuron.2014.05.041. Review.

5.

Alzheimer's disease risk genes and mechanisms of disease pathogenesis.

Karch CM, Goate AM.

Biol Psychiatry. 2015 Jan 1;77(1):43-51. doi: 10.1016/j.biopsych.2014.05.006. Epub 2014 May 17. Review.

PMID:
24951455
6.

Genetic discoveries in AD using CSF amyloid and tau.

Cruchaga C, Ebbert MT, Kauwe JS.

Curr Genet Med Rep. 2014 Mar 1;2(1):23-29.

7.

Genetic modification of the relationship between phosphorylated tau and neurodegeneration.

Hohman TJ, Koran ME, Thornton-Wells TA; Alzheimer's Disease Neuroimaging Initiative.

Alzheimers Dement. 2014 Nov;10(6):637-645.e1. doi: 10.1016/j.jalz.2013.12.022. Epub 2014 Mar 20.

PMID:
24656848
8.

Fyn kinase inhibition as a novel therapy for Alzheimer's disease.

Nygaard HB, van Dyck CH, Strittmatter SM.

Alzheimers Res Ther. 2014 Feb 5;6(1):8. doi: 10.1186/alzrt238. eCollection 2014. Review.

9.

Missense variant in TREML2 protects against Alzheimer's disease.

Benitez BA, Jin SC, Guerreiro R, Graham R, Lord J, Harold D, Sims R, Lambert JC, Gibbs JR, Bras J, Sassi C, Harari O, Bertelsen S, Lupton MK, Powell J, Bellenguez C, Brown K, Medway C, Haddick PC, van der Brug MP, Bhangale T, Ortmann W, Behrens T, Mayeux R, Pericak-Vance MA, Farrer LA, Schellenberg GD, Haines JL, Turton J, Braae A, Barber I, Fagan AM, Holtzman DM, Morris JC; 3C Study Group; EADI consortium; Alzheimer's Disease Genetic Consortium (ADGC); Alzheimer's Disease Neuroimaging Initiative (ADNI); GERAD Consortium, Williams J, Kauwe JS, Amouyel P, Morgan K, Singleton A, Hardy J, Goate AM, Cruchaga C.

Neurobiol Aging. 2014 Jun;35(6):1510.e19-26. doi: 10.1016/j.neurobiolaging.2013.12.010. Epub 2013 Dec 21.

10.

Rare coding variants in the phospholipase D3 gene confer risk for Alzheimer's disease.

Cruchaga C, Karch CM, Jin SC, Benitez BA, Cai Y, Guerreiro R, Harari O, Norton J, Budde J, Bertelsen S, Jeng AT, Cooper B, Skorupa T, Carrell D, Levitch D, Hsu S, Choi J, Ryten M; UK Brain Expression Consortium, Hardy J, Ryten M, Trabzuni D, Weale ME, Ramasamy A, Smith C, Sassi C, Bras J, Gibbs JR, Hernandez DG, Lupton MK, Powell J, Forabosco P, Ridge PG, Corcoran CD, Tschanz JT, Norton MC, Munger RG, Schmutz C, Leary M, Demirci FY, Bamne MN, Wang X, Lopez OL, Ganguli M, Medway C, Turton J, Lord J, Braae A, Barber I, Brown K; Alzheimer’s Research UK Consortium, Passmore P, Craig D, Johnston J, McGuinness B, Todd S, Heun R, Kölsch H, Kehoe PG, Hooper NM, Vardy ER, Mann DM, Pickering-Brown S, Brown K, Kalsheker N, Lowe J, Morgan K, David Smith A, Wilcock G, Warden D, Holmes C, Pastor P, Lorenzo-Betancor O, Brkanac Z, Scott E, Topol E, Morgan K, Rogaeva E, Singleton AB, Hardy J, Kamboh MI, St George-Hyslop P, Cairns N, Morris JC, Kauwe JS, Goate AM.

Nature. 2014 Jan 23;505(7484):550-4. doi: 10.1038/nature12825. Epub 2013 Dec 11.

11.

The SORL1 gene and convergent neural risk for Alzheimer's disease across the human lifespan.

Felsky D, Szeszko P, Yu L, Honer WG, De Jager PL, Schneider JA, Malhotra AK, Lencz T, Ikuta T, Pipitone J, Chakravarty MM, Lobaugh NJ, Mulsant BH, Pollock BG, Kennedy JL, Bennett DA, Voineskos AN.

Mol Psychiatry. 2014 Oct;19(10):1125-32. doi: 10.1038/mp.2013.142. Epub 2013 Oct 29.

12.

Genetic analysis of quantitative phenotypes in AD and MCI: imaging, cognition and biomarkers.

Shen L, Thompson PM, Potkin SG, Bertram L, Farrer LA, Foroud TM, Green RC, Hu X, Huentelman MJ, Kim S, Kauwe JS, Li Q, Liu E, Macciardi F, Moore JH, Munsie L, Nho K, Ramanan VK, Risacher SL, Stone DJ, Swaminathan S, Toga AW, Weiner MW, Saykin AJ; Alzheimer’s Disease Neuroimaging Initiative.

Brain Imaging Behav. 2014 Jun;8(2):183-207. doi: 10.1007/s11682-013-9262-z. Review.

13.

The PSEN1, p.E318G variant increases the risk of Alzheimer's disease in APOE-ε4 carriers.

Benitez BA, Karch CM, Cai Y, Jin SC, Cooper B, Carrell D, Bertelsen S, Chibnik L, Schneider JA, Bennett DA; Alzheimer's Disease Neuroimaging Initiative; Genetic and Environmental Risk for Alzheimer's Disease Consortium GERAD, Fagan AM, Holtzman D, Morris JC, Goate AM, Cruchaga C.

PLoS Genet. 2013;9(8):e1003685. doi: 10.1371/journal.pgen.1003685. Epub 2013 Aug 22.

14.

Genetics of Alzheimer's disease.

Ridge PG, Ebbert MT, Kauwe JS.

Biomed Res Int. 2013;2013:254954. doi: 10.1155/2013/254954. Epub 2013 Jul 25. Review.

15.

Approach to cerebrospinal fluid (CSF) biomarker discovery and evaluation in HIV infection.

Price RW, Peterson J, Fuchs D, Angel TE, Zetterberg H, Hagberg L, Spudich S, Smith RD, Jacobs JM, Brown JN, Gisslen M.

J Neuroimmune Pharmacol. 2013 Dec;8(5):1147-58. doi: 10.1007/s11481-013-9491-3. Epub 2013 Aug 13. Review.

16.

The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception.

Weiner MW, Veitch DP, Aisen PS, Beckett LA, Cairns NJ, Green RC, Harvey D, Jack CR, Jagust W, Liu E, Morris JC, Petersen RC, Saykin AJ, Schmidt ME, Shaw L, Shen L, Siuciak JA, Soares H, Toga AW, Trojanowski JQ; Alzheimer's Disease Neuroimaging Initiative.

Alzheimers Dement. 2013 Sep;9(5):e111-94. doi: 10.1016/j.jalz.2013.05.1769. Epub 2013 Aug 7. Review.

17.

The future of blood-based biomarkers for Alzheimer's disease.

Henriksen K, O'Bryant SE, Hampel H, Trojanowski JQ, Montine TJ, Jeromin A, Blennow K, Lönneborg A, Wyss-Coray T, Soares H, Bazenet C, Sjögren M, Hu W, Lovestone S, Karsdal MA, Weiner MW; Blood-Based Biomarker Interest Group.

Alzheimers Dement. 2014 Jan;10(1):115-31. doi: 10.1016/j.jalz.2013.01.013. Epub 2013 Jul 11. Review.

18.

Beyond amyloid: getting real about nonamyloid targets in Alzheimer's disease.

Herrup K, Carrillo MC, Schenk D, Cacace A, Desanti S, Fremeau R, Bhat R, Glicksman M, May P, Swerdlow R, Van Eldik LJ, Bain LJ, Budd S.

Alzheimers Dement. 2013 Jul;9(4):452-458.e1. doi: 10.1016/j.jalz.2013.01.017.

19.

Variants in PPP3R1 and MAPT are associated with more rapid functional decline in Alzheimer's disease: the Cache County Dementia Progression Study.

Peterson D, Munger C, Crowley J, Corcoran C, Cruchaga C, Goate AM, Norton MC, Green RC, Munger RG, Breitner JC, Welsh-Bohmer KA, Lyketsos C, Tschanz J, Kauwe JS; Alzheimer's Disease Neuroimaging Initiative.

Alzheimers Dement. 2014 May;10(3):366-71. doi: 10.1016/j.jalz.2013.02.010. Epub 2013 May 30.

20.

Genetic loci associated with Alzheimer's disease and cerebrospinal fluid biomarkers in a Finnish case-control cohort.

Elias-Sonnenschein LS, Helisalmi S, Natunen T, Hall A, Paajanen T, Herukka SK, Laitinen M, Remes AM, Koivisto AM, Mattila KM, Lehtimäki T, Verhey FR, Visser PJ, Soininen H, Hiltunen M.

PLoS One. 2013;8(4):e59676. doi: 10.1371/journal.pone.0059676. Epub 2013 Apr 3.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk